Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Digoxin | Canrenoic acid may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Acetyldigitoxin | Canrenoic acid may decrease the excretion rate of Acetyldigitoxin which could result in a higher serum level. |
| Deslanoside | Canrenoic acid may decrease the excretion rate of Deslanoside which could result in a higher serum level. |
| Ouabain | Canrenoic acid may decrease the excretion rate of Ouabain which could result in a higher serum level. |
| Digitoxin | Canrenoic acid may decrease the excretion rate of Digitoxin which could result in a higher serum level. |
| Oleandrin | Canrenoic acid may decrease the excretion rate of Oleandrin which could result in a higher serum level. |
| Cymarin | Canrenoic acid may decrease the excretion rate of Cymarin which could result in a higher serum level. |
| Proscillaridin | Canrenoic acid may decrease the excretion rate of Proscillaridin which could result in a higher serum level. |
| Metildigoxin | Canrenoic acid may decrease the excretion rate of Metildigoxin which could result in a higher serum level. |
| Lanatoside C | Canrenoic acid may decrease the excretion rate of Lanatoside C which could result in a higher serum level. |
| Gitoformate | Canrenoic acid may decrease the excretion rate of Gitoformate which could result in a higher serum level. |
| Acetyldigoxin | Canrenoic acid may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level. |
| Peruvoside | Canrenoic acid may decrease the excretion rate of Peruvoside which could result in a higher serum level. |
| Cyclosporine | The risk or severity of hyperkalemia can be increased when Canrenoic acid is combined with Cyclosporine. |
| Taxifolin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Taxifolin is combined with Canrenoic acid. |
| Licofelone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Licofelone is combined with Canrenoic acid. |
| Polmacoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Polmacoxib is combined with Canrenoic acid. |
| Ebselen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ebselen is combined with Canrenoic acid. |
| Flurbiprofen axetil | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen axetil is combined with Canrenoic acid. |
| Icosapent | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Canrenoic acid. |
| Mesalazine | The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Canrenoic acid. |
| Nabumetone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Canrenoic acid. |
| Ketorolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Canrenoic acid. |
| Tenoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Canrenoic acid. |
| Celecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Canrenoic acid. |
| Tolmetin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Canrenoic acid. |
| Rofecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Canrenoic acid. |
| Fenoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Canrenoic acid. |
| Valdecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Canrenoic acid. |
| Diclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Canrenoic acid. |
| Sulindac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Canrenoic acid. |
| Mefenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Canrenoic acid. |
| Naproxen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Canrenoic acid. |
| Sulfasalazine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Canrenoic acid. |
| Phenylbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Canrenoic acid. |
| Carprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Canrenoic acid. |
| Salicylic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Canrenoic acid. |
| Balsalazide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Canrenoic acid. |
| Lumiracoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Canrenoic acid. |
| Magnesium salicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Canrenoic acid. |
| Salsalate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Canrenoic acid. |
| Choline magnesium trisalicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Choline magnesium trisalicylate is combined with Canrenoic acid. |
| Antrafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antrafenine is combined with Canrenoic acid. |
| Aminophenazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Canrenoic acid. |
| Antipyrine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Canrenoic acid. |
| Tiaprofenic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Canrenoic acid. |
| Etoricoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Canrenoic acid. |
| Oxyphenbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Canrenoic acid. |
| Nimesulide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Canrenoic acid. |
| Benoxaprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Canrenoic acid. |
| Metamizole | The risk or severity of hyperkalemia can be increased when Metamizole is combined with Canrenoic acid. |
| Zomepirac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Canrenoic acid. |
| Cimicoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Cimicoxib is combined with Canrenoic acid. |
| Lornoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Canrenoic acid. |
| Zaltoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Canrenoic acid. |
| Azapropazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Canrenoic acid. |
| Parecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Canrenoic acid. |
| Salicylamide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Canrenoic acid. |
| Kebuzone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Canrenoic acid. |
| Isoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Canrenoic acid. |
| Indoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indoprofen is combined with Canrenoic acid. |
| Ibuproxam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuproxam is combined with Canrenoic acid. |
| Floctafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Canrenoic acid. |
| Fenbufen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Canrenoic acid. |
| Etofenamate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Canrenoic acid. |
| Epirizole | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Canrenoic acid. |
| Dexibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexibuprofen is combined with Canrenoic acid. |
| Droxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Canrenoic acid. |
| Tolfenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic acid is combined with Canrenoic acid. |
| Firocoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Firocoxib is combined with Canrenoic acid. |
| Clonixin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Clonixin is combined with Canrenoic acid. |
| Morniflumate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Morniflumate is combined with Canrenoic acid. |
| Talniflumate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Talniflumate is combined with Canrenoic acid. |
| Robenacoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Robenacoxib is combined with Canrenoic acid. |
| Tepoxalin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tepoxalin is combined with Canrenoic acid. |
| Flunixin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flunixin is combined with Canrenoic acid. |
| Nitroaspirin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nitroaspirin is combined with Canrenoic acid. |
| Indobufen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indobufen is combined with Canrenoic acid. |
| Tinoridine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tinoridine is combined with Canrenoic acid. |
| Fentiazac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fentiazac is combined with Canrenoic acid. |
| Suxibuzone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Suxibuzone is combined with Canrenoic acid. |
| Bumadizone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bumadizone is combined with Canrenoic acid. |
| Alminoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Canrenoic acid. |
| Difenpiramide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Difenpiramide is combined with Canrenoic acid. |
| Nifenazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nifenazone is combined with Canrenoic acid. |
| Lonazolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lonazolac is combined with Canrenoic acid. |
| Tenidap | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenidap is combined with Canrenoic acid. |
| Propyphenazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propyphenazone is combined with Canrenoic acid. |
| Proglumetacin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proglumetacin is combined with Canrenoic acid. |
| Guacetisal | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Guacetisal is combined with Canrenoic acid. |
| Ethenzamide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ethenzamide is combined with Canrenoic acid. |
| Carbaspirin calcium | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carbaspirin calcium is combined with Canrenoic acid. |
| Mofebutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mofebutazone is combined with Canrenoic acid. |
| Proquazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proquazone is combined with Canrenoic acid. |
| Benorilate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benorilate is combined with Canrenoic acid. |
| Pirprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pirprofen is combined with Canrenoic acid. |
| Imidazole salicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Imidazole salicylate is combined with Canrenoic acid. |
| SC-236 | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when SC-236 is combined with Canrenoic acid. |
| NS-398 | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when NS-398 is combined with Canrenoic acid. |
| Indomethacin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Canrenoic acid. |